Deutsche Bank Aktiengesellschaft reiterated their buy rating on shares of Koninklijke DSM (OTCMKTS:RDSMY) in a research report released on Thursday morning, The Fly reports.
Other equities research analysts also recently issued reports about the company. UBS Group reiterated a buy rating on shares of Koninklijke DSM in a report on Tuesday, August 24th. ING Group upgraded Koninklijke DSM from a sell rating to a buy rating in a report on Wednesday. JPMorgan Chase & Co. downgraded Koninklijke DSM from an overweight rating to a neutral rating in a report on Wednesday, September 1st. Morgan Stanley reiterated an equal weight rating on shares of Koninklijke DSM in a report on Wednesday, August 4th. Finally, Barclays raised their price objective on Koninklijke DSM from €168.00 ($197.65) to €189.00 ($222.35) and gave the stock an overweight rating in a report on Thursday, September 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Koninklijke DSM currently has an average rating of Hold and a consensus price target of $119.00.
Shares of OTCMKTS RDSMY opened at $55.39 on Thursday. The business’s 50 day moving average price is $51.58 and its 200-day moving average price is $47.31. Koninklijke DSM has a fifty-two week low of $38.65 and a fifty-two week high of $55.39. The company has a market cap of $40.20 billion, a price-to-earnings ratio of 67.55, a PEG ratio of 2.55 and a beta of 0.79.
Koninklijke DSM Company Profile
Koninklijke DSM NV engages in the manufacturing and sale of nutritional and pharmaceutical ingredients, and industrial chemicals. It operates through the following segments: Nutrition, Materials, and Innovation Center. The Nutrition segment comprises of the DSM Nutritional Products and DSM Food Specialties business groups.
Read More: Determine Your Level of Risk Tolerance
Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.